LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by Barclays PLC

Barclays PLC raised its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 273.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 16,463 shares of the company’s stock after buying an additional 12,051 shares during the period. Barclays PLC’s holdings in LENZ Therapeutics were worth $391,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Parkman Healthcare Partners LLC acquired a new position in shares of LENZ Therapeutics during the third quarter valued at approximately $3,308,000. The Manufacturers Life Insurance Company bought a new position in LENZ Therapeutics during the 3rd quarter valued at $743,000. Bank of New York Mellon Corp increased its position in shares of LENZ Therapeutics by 255.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company’s stock valued at $687,000 after purchasing an additional 28,556 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of LENZ Therapeutics by 197.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after buying an additional 81,901 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of LENZ Therapeutics by 18.7% in the third quarter. State Street Corp now owns 289,154 shares of the company’s stock valued at $6,865,000 after buying an additional 45,600 shares during the period. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Stock Up 0.6 %

Shares of NASDAQ LENZ opened at $28.46 on Friday. LENZ Therapeutics, Inc. has a 12 month low of $14.42 and a 12 month high of $38.93. The business has a fifty day simple moving average of $32.55 and a 200-day simple moving average of $25.89.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same quarter in the previous year, the business earned ($1.33) EPS. Equities research analysts forecast that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.

Analyst Ratings Changes

LENZ has been the topic of a number of research analyst reports. Raymond James started coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.